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Background
Quality of Life (QoL) data from oncology trials may
have missing data which cannot be assumed to be miss-
ing completely at random (MCAR) [1]. Ignoring this
missing data in analysis may introduce bias. A number
of statistical techniques to deal with informative missing
data are available [2], but may be underutilised.
Methods
We searched MEDLINE (2002-2012) to identify oncol-
ogy trials reporting longitudinal analysis of QOL data.
The appropriateness of the analysis was reviewed and
trials reporting QOL as primary/secondary endpoint
were assessed for reporting quality using the CONSORT
extension for PROs [3].
Results
69 RCTs reporting longitudinal QOL analyses were
identified. 29 (42%) use an analysis to account for the
nature of the missing data. Methods varied widely, eg
pattern-mixture models, conditional linear models,
QTWiST, joint longitudinal models, generalised estimat-
ing equations, selection models and Markov models.
Fourteen papers used more than one method check the
robustness of their results.
Conclusions
In order for QOL data to adequately inform clinical
decision-making the correct analysis needs to be per-
formed. Statistical methods ignoring the missing data
were found to over-estimate QOL but it was rare for
the significance of QOL differences between treatments
to change. A strategy for appropriate analysis of QOL
data will be presented using case studies to highlight
where ignoring informative missing data could alter the
conclusions regarding treatment differences.
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